Is OmniAb, Inc. (NASDAQ:OABI) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating OmniAb, Inc. at current levels.
A picks-and-shovels antibody discovery engine trading like a broken biotech, with royalty streams that could compound for a decade.
Where OABI is headed
OmniAb sits inside roughly 350 active partner programs, and the ones that matter are moving up the clinical ladder. By 2028, the company should have 8-12 partner molecules in Phase 3 or approved, up from a handful today. That is the moment the business model stops looking like a research-tools story and starts looking like what it actually is: a diversified antibody royalty book with 98% gross margins and near-zero marginal cost per partner win. Teva's TEV-'749 for schizophrenia, Immunovant's IMVT-1402, Roivant's batoclimab, and Merus's petosemtamab (yes, Merus programs sit inside partner pipelines that touch OmniAb technology in various ways) are the visible tip. Behind them is a long tail of programs where OmniAb collects milestones and mid-single-digit royalties whether the partner is a top-20 pharma or a Series B biotech.
Read the full Compass Direction on OABI
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.57).
See the full OABI analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is OmniAb, Inc. (NASDAQ:OABI) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating OmniAb, Inc. at current levels. A picks-and-shovels antibody discovery engine trading like a broken biotech, with royalty streams that could compound for a decade.
What is OABI's Compass Score?
OmniAb, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for OABI?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the OABI page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.